Annual index 2003
Article Outline
Author index
Aboukameel, A., 313
Adamia, S., 165
Aguilera, C., 187
Ahles, T, 749
Ahuja, R., 94
Al-Katib, A., 110
Al-Katib, A.M., 313
Aleman, A., 286
Alexanian, R., 116, 206, 243
Amess, J.A.L.A., 236
Amols, H.I., 596
Anagnostopoulos, A., 121
Anagnostopoulos, N., 265, 286
Anderson, C.M., 369
Anderson, K., 121
Anderson, K.C., 156, 248, 309
Angelopoulou, M.K., 201
Arriagada, R., 38
Avet-Loiseau, H., 153
Aymerich, M., 178
Azzoli, C.G., 79
Bárez, A., 187
Bagnell, S., 587
Baldini, L., 211
Bander, N.H., 667
Barbarano, L., 172
Barlogie, B., 116, 220, 282
Barrans, S.L., 161
Bartlett, N.L., 448
Bataille, R., 153
Bay, J.O., 291
Belch, A.R., 132, 165
Bennett, B.L., 275
Bernuzzi, P., 231
Björkholm. M., 116, 226
Bladé, J., 127, 178, 329
Blum, K.A., 448
Bosch, F., 178
Branagan, A.R., 110, 116, 121, 127
Broglia, C., 211
Bruenke, J., 465
Bruner, R.J., 509
Bugge, T.A., 545
Burman, C.M., 596
Burstein, H.J, 817
Byrd, J.C., 127, 421, 483
Cabanillas, F., 206
Cahn, J.Y., 291
Canesi, B., 172
Carducci, M.A., 678
Carrotte-Lefebvre, I., 216
Cavanna, L., 172
Cazin, B., 216, 291
Celsing, F., 226
Cesana, C., 172, 231
Cesano, A., 253, 457
Chirgwin, J.M., 717
Chlebowski, R.T, 776
Cho, D., 567
Choquet, S., 239
Christianson, D.F., 369
Chui, C-S., 596
Col, N.F, 776
Coleman, M., 121, 270, 457
Colomer, D., 424
Comelli, M., 211
Crainie, M., 165
Crowley, J.J., 220
Cuello, R., 187
Curtin, J.P., 401
D’Avanzo, G., 231
Davidson, N.E., 338
Dechant, M., 465
Delasalle, K., 206, 243
Demark-Wahnefried, W, 789
Desablens, B., 291
Detourmignies, L., 216
Dhodapkar, M., 116
Dhodapkar, M.V., 220, 305
Di Blasio, C.J., 567
Dillman, R.O., 434
Dimopoulos, M., 107, 206
Dimopoulos, M.A., 110, 243, 265
Dimopoulou, M.N., 201
DiPaolo, R.S., 390
Divine, M., 291
Doll, D.C., 337
Dreyfus, B., 291
Eberhardt, S.C., 616
Economopoulos, T., 265
Emens, L.A., 338
Emmanouilides, C., 127, 248, 258, 531
Epstein, K.R., 86
Erridge, S.C., 26
Escribano, L., 187
Esteve, J., 178
Farag, S.S., 509
Ferrer, A., 178
Filippini, D., 231
Flinn, I.W., 520
Fong, L., 649
Fonseca, R., 110, 142
Forconi, F., 136
Frankel, A.E., 545
Frankel, S., 248
Frankel, S.R., 121, 300
Fuks, Z., 596
Galsky, M., 689
Garand, R., 153
Garcı́a-Frade, J., 187
Gavino, M., 243
Gayko, U., 253
Gerald, W.L., 635
Gertz, M.A., 121, 220, 325
Giné, E., 178
Ginsberg, R.J., 47
Giralt, S., 121, 286
Glisson, B.S., 72
Gobbi, P.G., 211
Goldaniga, M., 211
Goldenberg, D.M., 457
Goldsmith, S.J., 667
Gomez, J., 79
Gregor, P.D., 659
Greipp, P.R., 110, 262
Gressin, R., 291
Guise, T.A., 717
Hamilos, G., 265
Hanson, C.A., 182
Hayman, S., 262
Hernández, J., 187
Hillmen, P., 493
Hodnefield, J.M., 182
Hricak, H., 616
Hunt, M., 596
Jack, A.S., 161
Jackson, A., 596
Jacobson, J.L., 220
Jahrsörfer, B., 476
Johansson, E., 226
Kantoff, P.W., 698
Kattan, M.W., 567
Keele, B., 248
Kelliher, A., 248
Kelly, W.K., 689
Kim, J.A, 776
Kimby, E., 127, 248
Kittas, C., 201
Klersy, C., 172
Klotz, L., 587
Kondagunta, G.V., 382
Kontopidou, F.N., 201
Kornblith, A.B, 799
Kostakoglu, L., 667
Kreitman, R.J., 545
Kriangkum, J., 132, 165
Kris, M.G., 79
Krug, L.M., 1, 79
Kurtin, P.J., 182
Kyle, R.A., 107, 116, 169, 182, 325
Kyrtsonis, M-C., 201
López, R., 187
López-Guillermo, A., 178
Lambertenghi, G., 211
Larson, D.R., 169
Lassiter, L.K., 678
Lazzarino, M., 172
Le Péchoux, C., 38
Leblond, V., 116, 216, 239, 291
Leibel, S.A., 596
Leibowitz, S.B., 698
Leitch, D., 161
Leonard, J., 270
Leonard, J.P., 457
Leone, F.T., 94
Leppla, S.H., 545
Levine, T., 121
Ligibel, J, 799
Lin, T.S., 483
Ling, C.C., 596
Link, B.K., 375
Lis, E., 616
Lister, T.A., 116, 226, 236
Lodé, L., 153
Logothetis, C.J., 562
Lucas, M.S., 483
Lyons, L., 270
Mageras, G.S., 596
Malek, S.N., 520
Mant, M.J., 132, 165
Margaritis, D., 265
Mateo, G., 187
Matesich, M.A, 740
Matsouka, C., 265
Matthews, J., 226
Mayer, R.J., 349
McElroy, Y.G., 318
McMaster, M.L., 110, 146
Melton, L.J. III, 169
Mensah-Osman, E., 313
Mercurio, F., 275
Merlini, G., 116, 211
Meyerhardt, J.A., 349
Miller, V.A., 1, 79
Milowsky, M.I., 667
Milpied, N., 291
Miqueleiz, S., 231
Mitsiades, C., 248
Mitsiades, C.S., 156, 309
Mitsiades, N., 156, 248, 309
Mohammad, R., 313
Montoto, S., 178, 329
Montserrat, E., 178, 329, 424
Morel, P., 116, 216
Moreton, P., 493
Moro, M.J., 187
Morra, E., 110, 172, 231
Motzer, R.J., 382
Munshi, N., 121
Munshi, N.C., 282
Murray, N., 26
Nadal, E., 178
Nanus, D.M., 667
Neville, D.M., 545
Newman, J.T., 318
Ngan, S., 236
Nichols, G.L., 297
Niesvizky, R., 270
Nordquist, L.T., 659
Norton, A., 236
Ocio, E., 187
Offord, J.R., 169
Onyebuchi, C.N., 616
Orfao, A., 187
Ottensmeier, C.H., 136
Owen, R.G., 110, 161, 196
Palladini, G., 211
Panayiotidis, P., 265
Pangalis, G.A., 110, 201
Papamichael, D., 226
Partridge, A.H, 817
Paskett, E.D, 814
Patel, J.D., 79
Patel, S.R., 413
Perrier, J.F., 291
Pestronk, A., 121, 318
Pignon, B., 291
Pilarski, L.M., 132, 165
Pisters, P.W.T., 413
Plevak, M.F., 169
Portero, J., 187
Preffer, F., 248
Pucar, D., 616
Rajkumar, S.V., 169, 262
Rajkumar, V., 121
Ramaswamy, B, 763
Rankin, K., 243
Remstein, E.D., 182
Reynolds, J.L., 318
Rhee, A.C., 567
Richardson, P.G., 309
Robillard, N., 153
Rock, C.L, 789
Rohatiner, A.Z.S., 226, 236
Rose, C., 216
Rosen, N., 709
Rosiñol, L., 178, 329
Rossi, V., 231
Rozman, M., 178
Rugo, H.S, 749
Sánchez, M.L., 187
Sánchez-Guijo, F., 187
Sahota, S.S., 136
Salgia, R., 57
San Miguel, J.F., 110, 187
Sandler, A.B., 9
Sattler, M., 57
Scardino, P.T., 567
Schöeder, H., 616
Schafer, P.H., 275
Scher, H.I., 616, 659, 709
Schlossman, R., 248
Schop, R.F.J., 142
Seidman, A.D, 730
Senecal, D., 291
Shahab, N., 337
Shapiro, C.L, 729, 740, 763
Sheinfeld, J., 382
Shepherd, F.A., 47
Siakantaris, M.P., 201
Siegel, A.B., 457
Slovin, S.F., 561, 659
Small, E.J., 649
Smith, T.J., 361
Solit, D.B., 709
Stalnikiewicz, L., 216
Stein, C.A., 297
Stevenson, F.K., 136
Stirling, D.I., 275
Stone, M., 116
Stone, M.J., 318
Szczesna, A., 47
Szczesny, T.J., 47
Szelenyi, H., 270
Tabrizi, R., 291
Tallman, M.S., 502
Taylor, B.J., 132
Theodoulou, M, 730
Therneau, T.M., 169
Tomblyn, M.R., 502
Tong, A.W., 318
Tournihac, O., 291
Travade, P., 291
Treon, S.P., 107, 110, 116, 121, 127, 132, 156, 248, 309
Tresoldi, E., 172, 231
Tsatalas, C., 265
Vaidya, A.P., 401
Valerius, T., 465
Vallabahajosula, S., 667
Varettoni, M., 172
Vassilakopoulos, T.P., 201
Vidriales, M.B., 187
Villamor, N., 424
Vinés, E.F., 38
Weber, D., 127, 206
Weber, D.M., 243
Weibel, S.B., 94
Weiner, G.J., 476
William, A., 236
Winer, E.P, 729, 817
Wolchok, J.D., 659
Wooldridge, J.E., 337, 375
Yao, S-L., 390
Zagars, G.K., 413
Zakowski, M.F., 3
Zeldis, J.B., 275
Zelefsky, M.J., 596
Zomas, A., 265
Subject index
Accuracy, 573–574
ACE chemotherapy regimen, in small cell lung cancer, 14–15
Acetate, 625
ACTIMID, 276
Actin cytoskeleton, in lung cancer, 64–65
Acute myeloid leukemia, incidence of, 502
Acute radiation-associated pericarditis, following early breast cancer therapy, 731
Age, stem cell transplantation and, 287–28
Albumin, serum, as prognostic factor, in Waldenstrom’s macroglobulinemia, 214–215
Alcohol, breast cancer and, 794
Alemtuzumab, 248–249, 422, 424, 429
administration of, 498
in B-cell malignancies, 494–495
in combination therapy, 496–497
dosing of, 443–444
hematological toxicity of, 498
infusion-related side effects of, 497
mechanism of, 498
mechanism of action of, 429–430
in non-Hodgkin’s lymphoma, 495–496
All-trans retinoic acid, 506
Alpha-carotene, chemical structure of, 87
Alzheimer’s disease, 755
American Gastroenterological Association, recommendations of, in colorectal cancer recurrence, 356–357
American Society for Therapeutic Radiation and Oncology consensus, in prostate specific antigen relapse, 568–569
American Society of Clinical Oncology
lung cancer follow-up guidelines of, 363, 364
recommendations of, in colorectal cancer recurrence, 356–357
Amyloidosis, 124
with monoclonal immunoglobulin M protein, 325–327
Anastrozole, 769–770
Androgen ablation therapy, in prostate cancer, 394–395
Androgen deprivation
intensity-modulated radiotherapy and, 611–612
radiotherapy and, 609–612
three-dimensional conformal radiotherapy and, 611–612
Androgen receptor, heat shock protein and, 710–711
Anemia, as prognostic factor, in Waldenstrom’s macroglobulinemia, 218–219
Angiogenesis
in prostate cancer, 679
in Waldenstrom’s macroglobulinemia, 262–263
Angiogenic growth factor, in prostate cancer, 589
Animal model, in human leukocyte antigen class II antibody trials, 468–470
Annexin V, 428
Ansamycin, clinical trials of, 713–714
Anthracycline(s)
cardiac toxicity of, 732–735
cardiotoxicity of, 735
liposomal, 736–737
Anti-B1, 429
Anti-CD3, 422, 551
Anti-CD20, radioisotope conjugates of, 488–489
Anti-CD20 therapy, 425–429
Anti-CD22 monoclonal antibodies
clinical applications of, 255–256
as therapeutic agents, 255
Anti-CD33 therapy, 430
Anti-CD52 therapy, 429–430
mechanism of resistance to, 430
Anti-CD55 monoclonal antibodies, 427
Anti-CD59 monoclonal antibodies, 427
Anti-CD7, 551
Anti-nuclear antibody, 318–323
Anti-transferrin receptor immunoconjugates, potency of, 549
Antibody dependent-cell mediated cytotoxicity, 425
rituximab and, 425–426
Anticarcinogenic substances, lung cancer and, 88
Anticytokine, 422
Antigen, in small cell lung cancer, 82
Antigen presenting cell, 650–651, 662
Antisense BCL-2, in small cell lung cancer, 76
Antithymocyte globulin, 510
Apolipoprotein E, 755
Apolizumab, 454
Apoptosis, 472
forward side scatter in, 427
in prostate cancer, 679
rituximab and, 428–429
side scatter in, 427
Aromatase, 769–770
Arrhythmia, following systemic chemotherapy, 732
Artifact, crush, 5
Atrasentan, 678
clinical responses to, 682
toxicities of, 682
Attention, following chemotherapy, 750
Autocrine growth loop, in small cell lung cancer, 75
Autologous bone marrow transplant, in small cell lung cancer chemotherapy, 15
AZD 4054, 678
B-chronic lymphocytic leukemia, treatment of, autoimmune complications in, 488
B43-PAP, 551
BA 12–9566, 81
Basic fibroblast growth factor, in prostate cancer, 589
bcl-2, 589
in small cell lung cancer, 76
bcl-2 antisense, cell death and, 301
bcl-2 antisense therapy, in Waldenstrom’s macroglobulinemia, 297–299
BCL-2 gene, in lung cancer, 58–59
bcl-10, 163
Bellergal, 782
Bence Jones protein, quantification of, 129–130
Benign prostate hyperplasia, 396
Beta-2 microglobulin
as prognostic factor, 214–215
levels of, 207, 209
Beta-carotene, 793
chemical structure of, 87
Beta-cryptoxanthin, chemical structure of, 87
Beta-emitter, properties of, 671
Bexxar, 258
Biomarker, in prostate cancer, 589–590
Biopsy, endomyocardial, in cardiotoxicity, 734
Bisphosphonates
actions of, 718–719
bone loss and, 721
cancer pain and, 720
effects of, on tumor, 720–721
prostate cancer and, 720
role of, in clinic, 719–720
BL22, 550–551
Black cohosh, 782
Blood pressure changes, following systemic chemotherapy, 732
Blue cell, 5
Bone, remodeling of, markers of, 717–718
Bone loss
chemotherapy-induced, 732, 766–767
ovarian failure and, 767
Bone metastasis, in prostate cancer, 626–630
Bone mineral density, 763
breast cancer risk and, 764
raloxifene and, 768
tamoxifen and, 768
Bone scan, 626–630
in breast cancer surveillance, 342–343
Bone scan index, 627–628
Bone scan study, in prostate cancer, 622
Bone scintigraphy, in prostate cancer, 621
Bone-derived growth factor, 718
Bootstrapping, 574
Bosentan, 678
Brachytherapy, 577–578
complications of, 582
contraindications to, 580
disadvantages of, 581
Brain metastasis, in small cell lung cancer, 38
Breast, reconstruction of, 802
Breast cancer
adjuvant chemotherapy of, 821
adjuvant therapy of, long-term effects of, 820
contralateral disease following, 817–819
diet and, 792–795
early-stage, overview of, 729
empowerment following, 814–816
estrogen and, 777–778
estrogen deficiency management in, 781–785
estrogen plus progestin and, 778–780
fertility issues following, 821–822
follow-up care following, 818
future research directions following, 808–810
hormonal therapy of, 821
hormone-replacement therapy and, 822–823
incidence of, 338, 730, 817
increased prevalence of, 338–339
lactation following, 822
local therapy complications in, 819–820
medical sequelae following, 806–807
obesity and, 789–792
positive psychological consequences following, 807
post-traumatic stress disorder and, 801
premenopausal, ovarian suppression in, 778
psychosocial adjustment following, 799–807
psychosocial interventions following, 807–808
psychosocial sequelae of, 823
radiotherapy for, second cancer following, 742, 743
recurrent, 817–819
relationships following, 804–805
risk of, and bone mineral density, 764
sexual functioning and, 802–804
stage of, and tumor markers, 341
support following, 805
survivors of, menopausal hormone therapy in, 780–781
Breast cancer relapse
menopause and, 339
patterns of, 339–343
screening for, 340
signs and symptoms of, 340
timing of, 339
Breast cancer surveillance
centralized v decentralized, 344–346
clinical trials of, 343
evidence-based, 346
Bupropion, 98
Bupropion SR, 99–100
Buserelin, 777–778
C-Kit, in lung cancer, 60
C-Met, in lung cancer, 60–62
C3, 426
C9, 426
C138, 133
CA-125, 410–411
following ovarian cancer, 402–403
CA15–3, breast cancer stage and, 341–342
CA27–29, breast cancer stage and, 341–342
Calcitriol, 692, 698–701
dosing of, 701–702
Calibration, 573
definition of, 572
Campath-1, 493–494
graft-versus-host disease and, 511–513
Campath-1H, 454
Cancer tumor
accelerated repopulation of, and chemoradiation, 28–29, 32
post-treatment, surveillance in, 337
Cancer Genome Anatomy Project, 639
Cancer prevention
carotenoid supplementation and, 89–91
nutritional substances for, 87–89
Cancer vaccine, see Tumor vaccine
Capromab pendetide, 668
Carbohydrate vaccine, 660–661
Carboplatin, cognitive effects following, 751
Carboplatin, paclitaxel regimen, in small cell lung cancer, 75
Carboplatin, cyclophosphamide, thiotepa regimen, cardiac effects of, 731
Carcinoembryonic antigen testing
breast cancer stage and, 341–342
colorectal cancer recurrence and, 351
Carcinoid tumorlet, 6
Cardiac dysfunction, following systemic chemotherapy, 732
Cardiac failure, following systemic chemotherapy, 732
Cardiac toxicity
of adjuvant doxorubicin, radiation therapy regimen, 731
of adjuvant therapy, in early breast cancer, 731
of anthracycline, 732–735
of radiation therapy, following breast-conserving surgery, 730–731
reduction of, associated with adjuvant chemotherapy, 736–737
trastuzumab-associated, 735–736
Cardiomyopathy, following systemic chemotherapy, 732
Cardioprotectant agents, 737
Carotenoid, 86–87
Caspase-3, 428
Caspase-9, 428
CAV chemotherapy regimen
in limited small cell lung cancer, 21
in small cell lung cancer, 11
topotecan v, 73, 74
CC-5013, 309–311
CCNU, in dose intensity trial, 13
CD5, 203
CD10, 203
CD16, 426
CD20, 133, 250, 425, 429
expression of, and complement-dependent cytotoxicity, 427
in lymphoproliferative disorders, 203
CD20 antigen, 483
CD22, 422
characterization of, 253
expression of, during B-lymphocyte development, 254
function of, 254–255
in immunotoxicin strategy, 461
as lymphoma immunotherapy target, 458–459
tissue distribution of, 253
CD22 alpha, 254
CD22 beta, 254
CD23, 203
CD32, 426
CD33, 422, 430
CD34, 263
CD38, 203
CD45, 422
CD52, 250
expression of, in B-lineage lymphoid malignancies, 498–499
CD52 antigen, 429
CD55, 426–427
CD59, 426–427
CD64, 426
Cell death, Bcl-2 antisense and, 301
Cell morphology, in lymphoproliferative disorders, 202–203
Cerrobend block, 597
Chemoradiation
duration of, 33–34
early, 28–29
fractionation in, 32–33
induction, in small cell lung cancer, 51–52
radiotherapy dose in, 32–33
sequential, 29–31
Chemoradiation package, 33–34
Chemotherapy
ACE regimen of, 14–15
adjuvant, in small cell lung cancer, 49–50
benefits of, v second cancer risk, 746
cisplatin, etoposide consolidation of, 11
CODE regimen of, 11–12
cognitive effects following, 751
combination, in small cell lung cancer, 74, 75
as consolidation therapy, 442
in diffuse large cell lymphoma, 448–453
dose dense, in small cell lung cancer, 14–15
dose intensity of, 12–14
dose-intensified, adjuvant, leukemia following, 744
early modality integration v sequential delivery of, 28, 29–31
escalating, with autologous bone marrow transplant, 15
EVI regimen of, 15
Goldie and Coldman hypothesis of, 11
high-dose, with stem cell support, 286–289, 291–295
leukemia following, 744
in low-grade lymphoma, 441
maintenance, clinical trials of, 10
mechanisms of, impacting cognitive function, 754–755
neoadjuvant, in small cell lung cancer, 50–51
neuropsychological impact of, 750–753
ovarian failure due to, 764–767
peripheral blood stem cell support with, 15
resistance to, chemoradiation and, 28
with rituximab, 440–442
second cancers following, 743–745
short intensive weekly, 11–12
in small cell lung cancer, 9–11
systemic, long-term side effects of, 731–732
V-ICE regimen of, 14–15
in Waldenstrom’s macroglobulinemia, 208–209
Chest radiography, colorectal cancer and, 351–352
Chlorambucil, 121
in Waldenstrom’s macroglobulinemia, 236–238
2-Chlorordeoxyadenosine, see Cladribine
Choline, 625
Chromosomal abnormalities
in small cell lung cancer, 57–58
in Waldenstrom’s macroglobulinemia, 143
Chromosome 3p, in small cell lung cancer, 57
Chronic lymphocytic leukemia, therapy of, infections and, 497–498
Cigarette smoking
lung cancer and, 94–95
nicotine dependence and, 97
nicotine replacement therapy and, 97–99
tobacco dependence and, 96
Ciglitazone, 309–311
Cisplatin
in dose-intensity trial, 13
in small cell lung cancer, 11, 15–16, 21
Cisplatin, etoposide regimen, 11
Cisplatin, ifosfamide, irinotecan regimen, 75
Cisplatin, ifosfamide, paclitaxel regimen, 75
Cisplatin, irinotecan regimen, 75
Cisplatin, paclitaxel, etoposide regimen, 21–22
Cisplatin, topotecan regimen, 75
Cladribine, 121, 122
re-treatment sensitivity with, 245
toxicity of, 245
in Waldenstrom’s macroglobulinemia, 208–209, 237, 243–247
Clarithromycin, 123
in combination therapy, 266–267
toxicity of, 272
in Waldenstrom’s macroglobulinemia, 270–273
Classification accuracy, 573–574
Clinical trial, two-arm phase III, sample size for, 35
Clodronate, oral, 769
Clonidine, 98, 100, 782, 783
CLOX, 757
CNS lymphoma, rituximab in, 452–453
CODE chemotherapy regimen, in small cell lung cancer, 11–12
Cognitive behavioral stress management , 759
Cognitive dysfunction, following systemic chemotherapy, 732
Cognitive function
chemotherapy mechanisms impacting on, 754–755
following adjuvant therapy, 749–750
hormonal influences on, 756–757
ongoing longitudinal trials studying, 753–754
CogState, 757–758
Cold agglutinin(s), 318–323
activity of, 137
Colonoscopy, colorectal cancer recurrence and, 352
Colorectal cancer
follow-up of, current practice patterns in, 356
incidence of, 349
oncology organization follow-up recommendations in, 356–357
Colorectal cancer recurrence
carcinoembryonic antigen testing and, 351
chemotherapy in, 350
chest radiography and, 351–352
colonoscopy and, 352
liver ultrasound and, 352
positron emission tomography with 18F-fluorodeoxyglucose and, 352–353
routine physical examination and, 350–351
surgery in, 349–350
Colorectal cancer surveillance
cost-benefit analysis of, 355
quality of life and, 355–356
randomized clinical trials of, 353–355
Combined modality therapy
duration of, 33–34
early modality integration v sequential delivery in, 28, 29–31
in limited-stage small cell lung cancer, 26–28
Complement-dependent cytotoxicity, 425, 467–468
CD20 expression and, 427
rituximab and, 426–427
Complementary-determining region, 424
Computed tomography
axial, in prostate cancer, 618
in breast cancer surveillance, 342–343
contrast-enhanced, in prostate cancer, 618
following ovarian cancer, 403–406
in prostate cancer, 622–623
recurrent prostate cancer and, 617–618
Concentration, following chemotherapy, 750
Concordance index, 573
Congestive heart failure, following systemic chemotherapy, 732
Conjugated equine estrogens, 782
Conjugated monoclonal antibody, definition of, 424
Consensus Panel I, 108
Consensus Panel II, 108
Consensus Panel III, 108
Consensus Panel IV, 108–109
Consolidation therapy, chemotherapy followed by rituximab as, 442
Contrast-enhanced Doppler ultrasound, in prostate cancer, 590
Coordination, following chemotherapy, 750
Cost-benefit analysis, of colorectal cancer surveillance, 355
CPT-11, in small cell lung cancer, 16–17
Cranial irradiation
clinical trials of, with neuropsychological assessment, 42
efficacy of, 42–44
future directions in, 45
neurocognitive outcomes with, 41–42
randomized trials of, 43, 44
shielding in, 45
in small cell lung cancer, 38–40
technical recommendations for, 44–45
toxicity of, 40–41
Cross-validation, 574
Crush artifact, 5
Cryoglobulinemia, 124
CTLA-4, 656
CWR22 human xenograft, 643
Cyclophosphamide
adjuvant, leukemia following, 744
cardiotoxicity of, 735
cognitive effects following, 751
in dose intensity trial, 13
neurotoxicity due to, 755
ovarian failure due to, 765–766
second cancer following, 743
Cyclophosphamide, doxorubicin regimen, cardiac effects of, 731
Cyclophosphamide, fluorouracil, epirubicin regimen, cardiac effects of, 731
Cyclophosphamide, methotrexate, fluorouracil regimen, cardiac toxicity of, 732–733
Cyclophosphamide, thiotepa, carboplatin regimen, cardiac effects of, 731
CYP-19, 769–770
Cytokine(s)
chemotherapy neurotoxic effects and, 754–755
as prostate cancer immunotherapy, 656
Cytomorphology, definition of, 112
Cytopenia, in Waldenstrom’s macroglobulinemia, 218
Cytoskeletal pathway, in lung cancer, 64–65
Cytotoxins, peptide class I, in hematologic neoplasm immunotoxins, 548
Daclizumab, 514
Data-splitting, 574
Daunorubicin, relative cardiotoxicity of, 733
Dendritic cell, 661, 662
in immunity, 306–307
as tumor vaccine, 649, 651
Dendritic cell-mediated immunization, 305–307
Dexamethasone, 123
in combination therapy, 266–267, 270–273
neurotoxicity due to, 755
toxicity of, 272
in Waldenstrom’s macroglobulinemia, 270–273
Dexrazoxane, 737
Diet, lung cancer and, 87–89
Dietary fiber, 793–794
Differentiation agent, 688
development of, obstacles to, 694–695
potential role of, 689
Diffuse large cell lymphoma, rituximab in, with chemotherapy, 448–453
Digital rectal examination, in prostate cancer, 616–617
Digitally reconstructed radiograph, 603
Dihydroethidine, 428
Dinitroflourobenzene, hapten, 660
Discrimination, definition of, 572–573
DNA vaccination, 662–663
Docetaxel, 73
in small cell lung cancer, 16–17
Dose-volume histogram, 599, 601
Doxil, 736–737
Doxorubicin
cardiac toxicity following, 732–733
cognitive effects following, 751
in dose intensity trial, 13
neurotoxicity due to, 755
relative cardiotoxicity of, 733
scheduling of, and cardiotoxicity, 736
second cancer following, 743
Doxorubicin, cyclophosphamide regimen, cardiac effects of, 731
Doxorubicin, paclitaxel regimen, in small cell lung cancer, 75
Doxorubicin, radiotherapy regimen, cardiac effects of, 731
DT388GMCSF, 551
Dutcher bodies, in Waldenstrom’s macroglobulinemia, 183
E-cadherin, 589
E3 ligase inhibitor, 278–280
E99, 668–670
Effector cell-dependent cytotoxicity, 467–468
Electopherogram, GeneScan analysis, of PCR products, 167
Electrocardiographic changes, following systemic chemotherapy, 732
Endometrial biopsy, in screening, 344
Endomyocardial biopsy, in cardiotoxicity, 734
Endothelin, 589
in prostate cancer, 678–680
Endothelin axis, 677–678
Endothelin receptor, clinical studies of, 680–684
Epirubicin
adjuvant, cardiac effects of, 731
cognitive effects following, 751
leukemia following, 744
neurotoxicity due to, 755
relative cardiotoxicity of, 733
Epirubicin, cyclophosphamide, fluorouracil regimen, cardiac effects of, 731
Epratuzumab, 248–249, 444, 453–454, 459–461
clinical applications of, 255–256
efficacy of, 255
radiolabeled murine LL2 with, 459–460
rituximab with, 461
unlabeled, clinical studies with, 460–461
Yttrium 90-, 459–460
Erythropoietin, 759
Estradiol level, 779
Estradiol vaginal ring, 782, 783
Estramustine, oral, in prostate cancer, 565
Estramustine, etoposide regimen, in prostate cancer, 565
Estramustine, vinblastine regimen, in prostate cancer, 565
Estrogen
breast cancer risk of, 777–778, 783
cognitive function and, 756–757
progestin plus, and breast cancer, 778–780
Estrogen deficiency, management of, 782
in breast cancer, 776–777
Estrogen plus progestin products, revised FDA labeling for, 780
Estrone level, 779
ET-1, 678–680
Etoposide
in dose-intensity trial, 13
in palliative therapy, 15–16
in prostate cancer, 565
in small cell lung cancer, 11, 15–16, 21
Etoposide, cisplatin regimen, in small cell lung cancer, 11
Etoposide, estramustine regimen, in prostate cancer, 565
Etoposide, irinotecan regimen, in small cell lung cancer, 75
Etoposide, paclitaxel, cisplatin regimen, in limited small cell lung cancer, 21–22
European Society for Medical Oncology, recommendations of, in colorectal cancer recurrence, 356–357
EVI chemotherapy regimen, in small cell lung cancer, 15
Evidence-based follow-up, levels of, for guideline-making, 363
Executive functioning, following chemotherapy, 750
EXIT25, 757
Expanded prostate cancer index composite, 582
Expressed sequence tags, 636
External-beam radiotherapy, 576–577
complications of, 582
contraindications to, 580
conventional techniques in, 597–598
disadvantages of, 581
four-field approach in, 597
in localized prostate cancer, 596–597
rotational technique in, 597–598
Familial Waldenstrom’s macroglobulinemia
characteristics of, 146–147
epidemiology of, 146
immunologic characterization in, 147–150
FHIT gene, in small cell lung cancer, 57–58
Fibroblast growth factor, basic, in prostate cancer, 589
Fludarabine, 121, 122
stem cell collection and, 287
toxicity of, 241
in Waldenstrom’s macroglobulinemia, 221–224, 237, 239–241
Fluorouracil
adjuvant, leukemia following, 744
cognitive effects following, 751
myelodysplasia following, 744
neurotoxicity due to, 755
second cancer following, 743
Fluorouracil, cyclophosphamide, methotrexate regimen, cardiac toxicity of, 732–733
Fluorouracil, epirubicin, cyclophosphamide regimen, cardiac effects of, 731
Fluoxetine, 782, 784
Follicular lymphoma, rituximab in, 436–437
Forward side scatter, in apoptosis, 427
Fragile histidine triad gene, in small cell lung cancer, 57–58
Fruits, potentially anticarcinogenic substances in, 88
Fucosyl GM1, 82, 83
Fulvestrant, 768–769, 777
Functional Assessment of Cancer Therapy-Cog, 758
G-protein-coupled receptor, in lung cancer, 62
G3139, see Oblimersen sodium
Gabapentin, 782, 784
Gastrin-releasing peptide, in small cell lung cancer, 75
GD3, 82–83
Geldanamycin, 310, 710
Gemcitabine, 73
in small cell lung cancer, 17
Gemcitabine, paclitaxel regimen, in small cell lung cancer, 75
Gemtuzumab ozogamicin, 422, 502–503
with chemotherapy, 505–506
definition of, 430
initial trials of, 503
mechanisms of resistance to, 505
in secondary acute myeloid leukemia, 506–507
stem cell transplant strategies and, 506
toxicities of, 504–505
Gene expression, highest ranked differential, in metastatic prostate cancer, 644–645
Gene expression analysis
of androgen ablation-resistant prostate cancer, 642–643
of androgen response pathway, 642–643
data analysis and, 638
microarray-based, steps in, 637
of neoplastic prostate transformation, 639–641
and prognostic features, 641
of prostate cancer, 638–647
of prostate cancer progression, 641–642
technical aspects of, 636
tissue heterogeneity and, 637–638
transcript profiling methods in, 636
Generalizability, 572
GeneScan analysis, Electopherogram, 167
Genetic findings, in lymphoproliferative disorders, 204
Germ cell tumor(s)
follow-up recommendations for, 385–387
incidence of, 382
long-term therapy effects of, follow-up of, 388–389
treated, follow-up studies for, 387–388
tumor-node-metastasis stages of, 383
Germinal center, 136
Ginkgo biloba, 759
Ginseng, 759
Gleason grade, 574
Gleason sum, 574
Globo H hexasaccharide, 655
Goldie and Coldman hypothesis, 11
Goserelin, 777–778
Graft-versus-host disease
acute, prevention of, 511
chronic, 515–516
monoclonal antibody therapy in, 509–511
primary treatment of, 513
steroid-resistant, 513–514
Graft-versus-lymphoma effect, 289
Graft-versus-myeloma effect, 289
Graft-versus-Waldenstrom’s macroglobulinemia effect, 295
Granulocyte-macrophage colony-stimulating factor, 660
in dose-dense chemotherapy regimen, 14–15
rituximab with, 443
Halotestin, adjuvant, leukemia following, 744
HAS1, 165–166
HAS2, 166–167
HAS3, 166
Healthy lifestyle, for women, 769
Heat shock factor 1, 712
Heat shock protein, 662
in prostate cancer, 710–711
Heat shock protein 90, 710–711
as cancer therapy target, 711–713
molecular chaperone, inhibitors of, 309–311
Hemoglobin
levels of, 207, 209
as prognostic factor, 214–215
Hepatocyte growth factor, in lung cancer, 60–62
Hepsin, 589
HER2, 735
Herbal therapy, of estrogen deficiency, 784
High Sensitivity Cognitive Screen, 752
Histone, 692–693
Histone deacetylase inhibitor, 309–311
HIV-associated large cell lymphoma, rituximab in, 452
HLA-DR, 422
Hodgkin’s disease, lymphoctye-predominant, 440
Hodgkin’s lymphoma
follow-up cost in, 379
relapse characteristics in, 377
relapse detection in, 377–378
relapse in, 376
relapse symptoms in, 377
secondary, 378
surveillance in, evidece-based recommendations for, 379–380
treatment-related complication follow-up in, 378–379
Hopkins Symptom Checklist-25, 751
Hormonal therapy
cognitive function and, 756–757
second cancers following, 745–746
Hormone-replacement therapy, breast cancer and, 822–823
Hu1D10, 454, 470–471
Human epidermal growth factor receptor-2, 735
Human glandular kallikrein-2, 589
Human leukocyte antigen class II antibodies, 465–466
Human tumor control probability curve, 599
Humanized LL2, 459–461
Hyaluronan, in Waldenstrom’s macroglobulinemia, 165–167
Hyaluronan synthases, 165
Hyperviscosity syndrome, 124, 236
I Can Cope, 809–810
Ibritumomab, 444
Idarubicin, relative cardiotoxicity of, 733
IDEC-114, 454
Ifosfamide
in chemotherapy combination regimens, 18
in small cell lung cancer, 17
Ifosfamide, irinotecan, cisplatin regimen, 75
Ifosfamide, paclitaxel, cisplatin regimen, 75
IgG molecule, composition of, 424
IgRFB4-dgA, 551
Imatinib, 81
Immune modulatory drug, 275–277
Immunofixation, 129
Immunofluorescence assay, 669
Immunoglobulin, monoclonal, with antibody activity, 318–323
Immunoglobulin H region, switch translocations at, 143
Immunoglobulin M
amyloidosis with, 325–327
levels of, in Waldenstrom’s macroglobulinemia, 127–128, 207, 209
quantification of, 129
secretion of, 111
Immunoglobulin M monoclonal gammopathy
asymptomatic, 172
clinical characteristics of, 173
malignant transformation risk for, 174–175
Immunoglobulin M monoclonal gammopathy of undetermined significance
initial characteristics of, 179
long-term follow-up of, 169–171
malignant transformation risk for, 179–180
Immunoglobulin M monoclonal protein, concentration of, in Waldenstrom’s macroglobulinemia, 197
Immunoglobulin M myeloma, 198–199
Immunophenotypic study(ies)
in lymphoproliferative disorders, 203–204
in Waldenstrom’s macroglobulinemia, 185
Immunotherapy, clinical trials of, in prostate cancer, 652
Immunotoxicin strategy, CD22 in, 461
Immunotoxin therapy, in small cell lung cancer, 75–76
Immunotoxin(s)
clinical results with, 550–553
clinical trials of, 553–554
efficacy of, 550–551
immune responses of, 552
in vitro potency of, for hematologic malignancies, 546–547
pharmacokinetics of, 551–552
synthesis of, 545–550
toxicities of, 552–553
Indium 111-capromab pendetide, in prostate cancer, 622
Infertility, following systemic chemotherapy, 732
Inflizimab, 515
Insulin-like growth factor, in prostate cancer, 589
Insulin-like growth factor I, in lung cancer, 60
Intensity-modulated radiotherapy, 597, 602
androgen deprivation and, 611–612
characterization of, 600
computer-automated optimization in, 603–604
delivery of, 604–605
neoadjuvant androgen deprivation and, 611
rectal and urinary toxicity in, 606
template of, for prostate treatment plan, 604
Interferon-alpha, rituximab with, 442–443
Interleukin-2, 453
rituximab with, 443
Interleukin-12, 453
rituximab with, 443
International Prostate Symptom Score, 396
Iodine 111–tositumomab, 444
Iodine 131–radiolabeled Lym-1, 454
Iodine 131–tositumomab, 453, 538–539
clinical trials of, 539–540
toxicity of, 540–541
Irinotecan
in chemotherapy combination regimens, 20–21
in small cell lung cancer, 73
Irinotecan, cisplatin regimen, 75
Irinotecan, etoposide regimen, 75
Irinotecan, ifosfamide, cisplatin regimen, 75
J-415, 668–670, 672
J–533, 668–670
J-591, 654, 668–672
in prostate cancer, 622
radiolabeled human, phase I trials of, 672–673
in solid tumor malignancies, 675–676
Jackknife method, 574
Jun N-terminal kinase inhibitors, 277–278
activation of, 276
signaling cascade involving, 278
uses of, 278
Ki-67, 589
L-Pam, second cancer following, 743
L-phenyalanine mustard, second cancer following, 743
Large cell lymphoma, relapsed, rituximab in, 450
Large cell neuroendocrine cancer, 6
Latency period, 740
Left ventricular ejection fraction
evaluation of, guidelines for, 734
following chemotherapy, 734–735
Letrozole, 769–770
Leukemia, following adjuvant chemotherapy, 744–745
Liposomal anthracycline, 736–737
Liver ultrasound, colorectal cancer recurrence and, 352
LMB2, 551
Lung cancer
American Society of Clinical Oncology follow-up guidelines in, 363, 364
diet and, 87–89
follow-up guidelines in, 361–364
follow-up in, current practice of, 364–367
follow-up studies in, 365
following breast cancer radiotherapy, 743
incidence of, 86
intense follow-up in, reasons for, 366
smoking and, 86, 94–95
smoking cessation and, 95–96
Lung cancer surveillance
non-small cell, follow-up guidelines in, 361–363
patient concerns about, 362
physician concerns about, 362
small cell, follow-up in, 363–364
Lutein, chemical structure of, 87
Lycopene, chemical structure of, 87
Lym–1, 470
Lym–1 antibody, 454
Lymph node metastasis, in prostate cancer, 626
Lymphadenopathy, 130
Lymphedema, 820
Lymphoma
CNS, rituximab in, 452–453
diffuse large cell, 448–453
follicular, 436–437
HIV-associated large cell, 452
low-grade, rituximab dosing in, 438
lymphoplasmacytoid, 439–440
malt, 440
small lymphocytic, 439
Lymphoma
classification of, 375
curability of, 375–376
follow-up cost in, 379
relapse characteristics in, 377
relapse detection in, 377–378
relapse symptoms in, 377
response assesment in, 376
secondary, 378
surveillance in, evidece-based recommendations for, 379–380
treatment-related complication follow-up in, 378–379
Lymphoplasmacytic lymphoma, 108
definition of, 111–112
phenotypic profiles in, without M-component, 190
Lymphoplasmacytoid lymphoma, rituximab in, 439–440
Lymphoproliferative disorder
low-grade B-cell, v Waldenstrom’s macroglobulinemia, 202–204
with Waldenstrom’s macroglobulinemia features, 202
Magnetic resonance imaging
bone marrow survey with, 629
in breast cancer surveillance, 342–343
cognitive function and, 758
following ovarian cancer, 404–406
in prostate cancer, 590, 618–620
Magnetic resonance spectroscopy, in prostate cancer, 590, 620–621
Major histocompatibility complex class II antibodies, mechanisms of action of, 466–468
Malt lymphoma, characterization of, 440
Mammography, screening, 338–339
Marimstat, 81
Mastectomy, 802
Matrix metalloproteinase inhibitor, in small cell lung cancer, 80–81
Mcl-1 to Bax ratio, 428
Medroxyprogesterine acetate, 782
Megestrol acetate, 781–782
breast cancer risk of, 783
Melanoma
follow-up in, 372–373
incidence of, 369–370
natural history of, 370
prognosis in, 370
recurrence detection in, 370–372
second primary, risk for, 372
Melphalan, high-dose, in Waldenstrom’s macroglobulinemia, 282–284
Memory, following chemotherapy, 750
Menopause
breast cancer relapse and, 339
cognitive function and, 756–757
early, following systemic chemotherapy, 732
Metastasis
bone resorption in, 717
osteoblastic, 719
in prostate cancer, 679
reduced, chemoradiation and, 28
Methotrexate
adjuvant, leukemia following, 744
cognitive effects following, 751
in dose intensity trial, 13
neurotoxicity due to, 755
second cancer following, 743
Methotrexate, cyclophosphamide, fluorouracil regimen, cardiac toxicity of, 732–733
Methylphenidate, 759
Methylprednisolone, neurotoxicity due to, 755
Microvessel density, in Waldenstrom’s macroglobulinemia, 263
Minimal disease monitoring, stem cell graft purging and, 520–522
Mitogenesis, in prostate cancer, 678–679
Mitoxantrone, relative cardiotoxicity of, 733
Mitoxantrone, prednisone regimen, in prostate cancer, 565
MLC leaf position, 602, 603
Monoclonal antibody(ies)
conjugated, 424
in development, 453–454
radiolabeled, 522–524
to prostate-specific membrane antigen, 668–670
in small cell lung cancer, 75
unlabeled, in stem cell transplantation, 524–527
Monoclonal antibody 2A11, in small cell lung cancer, 75
Monoclonal antibody BEC2, 83
Monoclonal antibody imaging, in prostate cancer, 622
Monoclonal antibody N901, in small cell lung cancer, 75–76
Monoclonal antibody therapy
antibody structure in, 458
for B-cell malignancies antigenic targets, 458
combination, 249, 251
for hematologic malignancies, 421–423
main advantage of, 424
target selection in, 457–458
in Waldenstrom’s macroglobulinemia, 248–251
Monoclonal gammopathy of undetermined significance, 111
classification of, 113
criteria for, 112
IgM, long-term follow-up of, 169–171
Monoclonal immunoglobulin, with antibody activity, 318–323
Morel score, 230
Motor function, following chemotherapy, 750
Mouse xenograft model, in Waldenstrom’s macroglobulinemia, 313–316
Mt-SP1, 589
Multiple myeloma, response criteria for, and Waldenstrom’s macroglobulinemia, 329–331
MYC gene, in lung cancer, 58
Mycophenolate mofetil, 510
Myelodysplasia, following adjuvant chemotherapy, 744–745
Myocardial infarction, following systemic chemotherapy, 732
Myocarditis, following systemic chemotherapy, 732
National Comprehensive Cancer Network, recommendations of, in colorectal cancer recurrence, 356–357
Natural killer cell, 426, 467–468, 472
Natural products, in estrogen deficiency management, 784
Nephelometry, 129
Neural cell adhesion molecule, in lung cancer, 63
Neuroendocrine cancer, large cell, 6
Neuroendocrine lung tumor, diagnosis criteria for, 7
Neuropathy, 124
Neuropsychiatric testing, 757–758
Nicotine
dependence on, 97
novel treatments in, 100
Nicotine gum, 98, 99
Nicotine inhaler, 98, 99
Nicotine nasal spray, 98, 99
Nicotine patch, 97–98
Nicotine polacrilex, 99
Nicotine replacement therapy, 97–99
combination, 99
Nicotine straw, 100
Nicotine vaccine, 100
NKH-1, in small cell lung cancer, 75
Nomogram
brachytherapy calibration, 579
calibration of, 577, 578
definition of, 568
development of, 572–575
future of, 580–585
limitations of, 579–580
modeling considerations for, 574–575
Palm Pilot software for, 571
postoperative, for prostate cancer recurrence, 576
preoperative, calibration plot of, 573
for PSA recurrence, 578
treatment efficacy and, 578–579
usefulness of, 570–571
Non-Hodgkin’s lymphoma
follow-up cost in, 379
relapse characteristics in, 377
relapse detection in, 377–378
relapse in, 376–377
relapse symptoms in, 377
secondary, 378
surveillance in, evidece-based recommendations for, 379–380
treatment-related complication follow-up in, 378–379
Non-small cell lung cancer, follow-up guidelines in, 361–363
Nonseminoma
advanced, 384–385
chemotherapy-treated advanced, follow-up for, 386
early-stage, therapy for, 382–384
follow-up recommendations for, 385–387
stage I, 386
stage II, 385
stage III, 385
treatment of, 384
Nortriptyline, 98, 100
Notch receptor, in lung cancer, 62–63
Nuclear factor kappa B, activation of, 161–163
Nuclear-to-cytoplasmic ratio, high, 5
Nucleosome, 692–693
Obesity, breast cancer and, 789–792
Oblimersen sodium, 297–299
clinical studies of, 301–302
phase I-II trial of, 302
preclinical activity of, 301
in Waldenstrom’s macroglobulinemia, 297–299, 300–303
Oligodeoxynucleotides, immunostimulatory CpG, 476–480
One D10, 470–471
ONTAK, 551
Orchiectomy, in prostate cancer, 394–395
Organomegaly, 130
Osteoblast, 718
Osteoclast, 718
Osteogenesis, in prostate cancer, 679–680
Osteolytic factor, 718
Osteopenia, in breast cancer, 770–771
Osteoporosis
managing, in breast cancer, 770–771
pathogenesis of, 764
risk factors for, 766
Osteoporosis equation, 765
Osteoprotegrin, 763
Outcomes research, clinical end points in, of prostate cancer, 569
Ovarian cancer
physical examination following, 401–402
radiologic studies following, 403–406
second-look surgery in, 406–408
survival in, 402
tumor markers following, 402–403
Ovarian failure
bone loss and, 767
chemotherapy-induced, 764–767
Overfitting, 572
p13K pathway, in lung cancer, 63–64
p27, 589
p50, 163
p53, 589
in lung cancer, 59
p65, 163
Paclitaxel
cardiotoxicity of, 735
in combination chemotherapy regimens, 18–19
neurotoxicity due to, 755
in small cell lung cancer, 16–17, 73
Paclitaxel, carboplatin regimen, 75
Paclitaxel, doxorubicin regimen, 75
Paclitaxel, etoposide, cisplatin regimen, 21–22
Paclitaxel, gemcitabine regimen, 75
Paclitaxel, ifosfamide, cisplatin regimen, 75
Pain, due to ET-1, in prostate cancer, 680
Palliative therapy, in small cell lung cancer, 15–16
Paraprotein, 323
Paroxetine, 782, 784
Paroxysmal nocturnal hemoglobinuria, 430
Patients
intense lung cancer follow-up and, 366
lung cancer surveillance and, 362
PAX-5 gene, 204
Paxillin, 65
PDK1, in lung cancer, 63–64
Pericarditis
acute radiation-associated, 731
following systemic chemotherapy, 732
Peripheral blood stem cell support, in small cell lung cancer chemotherapy, 15
Peripheral blood stem cell transplantation
rituximab and, 450–451
in Waldenstrom’s macroglobulinemia, 282–284, 291–295
Peroxisome proliferator-activated receptor gamma ligands, 693–694
cancers and, 703
clinical data of, 705
liposarcoma and, 702–703
mechanisms of action of, 704–705
prostate cancer and, 703–704
PET, see Positron emission tomography
Phase II trial, of endothelin receptors, 681–684
Physicians
intense lung cancer follow-up and, 366
lung cancer surveillance and, 362
Pioglitazone, 694
Planning target volume, 599, 601
Plasma cell, in Waldenstrom’s macroglobulinemia, 183
Plasma cell disorders, angiogenesis in, 262
Plasmacytoid lymphocyte, in Waldenstrom’s macroglobulinemia, 183
Plasmapharesis, 124
Poly-adenosine diphosphate ribose polymerase, 428
Polymorphonuclear neutrophils, 468, 472
Positron emission tomography, 590
in breast cancer surveillance, 342–343
in cardiotoxicity, 734
cognitive function and, 758
colorectal cancer recurrence and, 352–353
following ovarian cancer, 405–406, 406
in limited small cell cancer, 21
in metastatic ovarian cancer, 407
in prostate cancer, 622–623, 625–626
Post-transplant lymphoproliferative disease, rituximab in, 451–452
Post-traumatic stress disorder, breast cancer and, 801
Practice effect, 757
Prednisone, mitoxantrone regimen, in prostate cancer, 565
Premarin, 779–780
Primates, in human leukocyte antigen class II antibody trials, 468–470
Prinomastat, 81
Profile of Mood States, 752
Progesterone, cognitive function and, 756
Progestin
breast cancer risk of, 783
estrogen plus, and breast cancer, 778–780
in vasomotor symptoms management, 781–782
Progestin plus estrogen product, revised FDA labeling for, 780
Prognostic factors, staging v, in Waldenstrom’s macroglobulinemia, 214–215
Prognostic scoring system, in Waldenstrom’s macroglobulinemia, 230
ProstaScint imaging, 622, 625, 628
lymph node metastases and, 626
ProstaScint scan, 588, 668
Prostasin, 589
Prostate acid phosphatase, 652–653
Prostate cancer
amphotropic phase of, 563–564
androgen ablation-resistant, 646–647
antigen ablation in, 565
bone-targeting therapies in, 565
classification of, 562
clinical end points in, 568–570
clonal expansion phase of, 564
computed tomography in, 617–618
digital rectal examination in, 616–617
disease progression in, 569–570
disease states in, 571
disease-free probability in, 569–570
disease-specific survival in, 569
follow-up options in, 397
follow-up recommendations in, 395–398
following hormone therapy, 709–710
heterotopic phase of, 564–565
immunotherapy trials in, 652
incidence of, 567
International Symptom Score in, 396
localized, competing risk analysis in, 591
locally recurrent, imaging detection of, 623–624
management of, 587–588
monoclonal antibody imaging in, 622
natural course of, 390–391
overall survival in, 569
progression of, classification of, 563
prostate specific antigen relapse in, 568–570
radiation complications in, 393
recurrence of, preoperative nomogram for, 568
recurrence staging in, 394
recurrent, 393–395
routine health maintenance in, 398
surgery complications in, 392–393
surgical v radiotherapeutic complications in, 393
therapy complications in, 582
therapy contraindications in, 580
therapy indications in, 580
therapy of, quality of life following, 391–392
transrectal sonography in, 617
treatment options in, 567
watchful waiting complications in, 391–392
watchful waiting in, 581
Prostate Intervention Versus Observation trial, 591
Prostate intraepithelial neoplasia, 588
Prostate specific antigen, relapse and, 568–570
Prostate transcriptome, in prostate cancer, 638–639
Prostate-specific antigen, 622, 649, 651–652, 655
in prostate cancer, 616–617
Prostate-specific antigen doubling time, 588, 650–651
in prostate cancer therapy selection, 591–592
Prostate-specific antigen testing, widespread use of, 590–591
Prostate-specific membrane antigen, 588–589, 649, 653–654, 668
in prostate cancer, 622, 662, 663
Prostatectomy, radical, 575–576, 581, 582, 619
Prostatic acid phosphatase, 649, 668
Proteasome inhibition, in Waldenstrom’s macroglobulinemia, 310
Protein
chaperone, 712
heat-shock, 662
Protein antigen vaccine, 661
Protein kinase C-alpha, in lung cancer, 64
Proteomic profiling, in Waldenstrom’s macroglobulinemia v multiple myeloma, 156–158
PS-341, 310
PSA, see Prostate-specific antigen
Psychomotor functioning, following chemotherapy, 750
PTEN gene, 647
Quality of life, 749
colorectal cancer surveillance and, 355–356
following prostate cancer therapy, 391–392
Quality-of-life measures, following chemotherapy, 750
R-CHOP regimen, 449–450
R-EPOCH regimen, 449–450
Radiation therapy
adjuvant, in early breast cancer, 730–731
of breast, second cancer following, 742
cardiac effects of, 730–731
second cancer related to, 741–743
Radiation therapy, doxorubicin regimen, cardiac effects of, 731
Radiation-associated pericarditis, following breast cancer therapy, 731
Radiation-assoicated vascular injury, following breast cancer therapy, 731
Radical prostatectomy, 575–576
complications of, 582
contraindications to, 580
disadvantages of, 581
magnetic resonance imaging in, 619
Radicicol, 712
Radiograph, digitally reconstructed, 603
Radioimmunoconjugates, elements of, 532–534
Radioimmunoscintigraphy
with ProstaScint, 628
in prostate cancer, 624–625
Radioimmunotherapy
incorporation of, in clinical practice, 541–542
targets for, 531–532
in Waldenstrom’s macroglobulinemia, 258–260
Radionuclide angiography, 734
Radiotherapy
androgen deprivation and, 609–612
benefits of, v second cancer risk, 746
complications of, 393
dosing of, in small cell lung cancer, 32–33
early modality integration v sequential delivery of, 28
early v delayed, clinical trials of, 30
external-beam, see External-beam radiotherapy
future direction of, in small cell lung cancer, 34–35
intensity-modulated, see Intensity-modulated radiotherapy
lung cancer following, 743
PET chemotherapy plus, 22
resistance to, chemoradiation and, 28
sequential, 29–31
three-dimensional conformal, 577
volume of, 31–32
Radiotracer, in prostate cancer, 625–626
Raloxifene, 767–768
bone mineral density and, 768
RAR-B gene, in small cell lung cancer, 58
RB gene, in lung cancer, 59–60
Reactive oxygen species, 427
Reactive oxygen species pathway, in lung cancer, 65–67
REAL classification, of Waldenstrom’s macroglobulinemia, 107–108
Receiver operating characteristic curve, 572–573
Receptor activator nuclear factor-kappa B ligand, 763
Replacement mutation, 138
Retinoic acid receptor, beta form of, 58
Retinoid(s)
in prostate cancer, 689–691
trials of, 690
Retinoid X receptor, 698
REVIMID, 276–277
Revised European and American Lymphoma classification, of Waldenstrom’s macroglobulinemia, 107–108
RHAMM, intracellular, 165, 166
Rheumatoid factor, 318–323
Risedronate, oral, 769
Risk-benefit analysis, of second cancer risk v adjuvant therapy, 746
Rituximab, 121, 122, 124, 238, 248–249, 256, 307, 421, 424, 457–458
additional dosing of, 437–439
antibody dependent-cell mediated cytoxicity and, 425–426
apoptosis and, 428–429
with chemotherapy, 440–441, 487
in CNS lymphomas, 452–453
in combination therapy, 486–487
complement-dependent cytotoxicity and, 426–427
as consolidation therapy, 442
with cytokines, 453
definition of, 425
in diffuse large cell lymphoma, 448–453
dimerization of, 429
dose-intensive schedules of, 486
dosing of, 438
epratuzumab with, 461
following chemotherapy, 441–442
granulocyte-macrophage colony stimulating factor with, 443
in HIV-associated large cell lymphoma, 452
infusion toxicity with, 489–490
interferon-alpha with, 442–443
interleukin-12 with, 443
interleukin-2 with, 443
in low-grade lymphoma, 441
in lymphoplasmacytoid lymphoma, 439–440
mechanisms of action of, 425, 484
mechanisms of resistance to, 429
with monoclonal antibodies, 487
new approaches with, 453
peripheral blood stem cell transplantation and, 450–451
in post-transplant lymphoproliferative disease, 451–452
prophylaxis against, toxicity with, 489
in purging, 282–284
in relapsed large cell lymphoma, 450
as single agent, 434–435
in small lymphocytic lymphoma, 439
stepped up dosing of, 489
toxicity of, 487–488
trials of, in follicular lymphoma, 436–437
in Waldenstrom’s macroglobunemia, 440
weekly, in B-chronic lymphocytic leukemia, 484–486
Rodents, in human leukocyte antigen class II antibody trials, 468–469
Rosiglazone, 695
Rosiglitazone, 309–311
Salt and pepper chromatin pattern, 5
Sarafotoxin, 680
Sarcoma
following breast cancer radiotherapy, 742
incidence of, 413–414
recurrence patterns in, 414
surveillance following, 414–415
Screening
for breast cancer relapse, 340
endometrial biopsy in, 344
mammography, 338–339
for therapy-related complications, of breast cancer, 344
Second cancer
adjuvant therapy benefits v, 746
following adjuvant chemotherapy, 743–745
following breast cancer radiotherapy, 742
following hormone therapy, 745–746
following systemic chemotherapy, 732
treatment-related, 740–741
Selective cytokine inhibitory drugs, 277
Selenium, Vitamin E, Chemoprevention Trial, 563–564
Self protein, 649
Seminoma
advanced, 384
early-stage, therapy for, 382
follow-up recommendations for, 385–387
radiation-treated stage I, follow-up for, 386
treated, follow-up studies for, 387–388
treatment of, 384
Serial analysis of gene expression, 636
Serotherapy
combination, 249, 251
in Waldenstrom’s macroglobulinemia, 248–251
Seven E11, 668–670, 672
Seventeen AAG, 709–714
Side scatter, in apoptosis, 427
Silent mutation, 138
Single-photon emission computed tomography
coronal, 623
indium 111–antimyosin, in cardiotoxicity, 734
in prostate cancer, 622, 627–630
Small cell lung cancer
ACE chemotherapy regimen in, 14–15
antigens in, 82
autologous bone marrow transplant in, 15
brain metastases in, 38
chemotherapy dosing intensity in, 12–14
chemotherapy duration in, 9
chemotherapy failure in, surgery following, 52–53
chemotherapy in, 9
chemotherapy trials in, 10
chromosomal abnormalities in, 57–58
cisplatin, etoposide consolidation therapy in, 11
CODE chemotherapy regimen in, 11–12
combination chemotherapy in, 74, 75
dose-dense chemotherapy in, 14–15
EVI chemotherapy regimen in, 15
follow-up in, 363–364
Goldie and Coldman chemotherapy hypothesis in, 11
growth factor abnormalities in, 60
immunotoxin therapy in, 75–76
incidence of, 9
maintenance chemotherapy in, 9–11
maintenance chemotherapy trials in, 10
matrix metalloproteinase inhibitor in, 80–81
minimal residual disease detection in, 79–80
monoclonal antibody therapy in, 75
neoadjuvant chemotherapy in, 50–51
optimal surgical approach in, 54
palliative therapy in, 15–16
pathology of, 4–7
peripheral blood stem cell support in, 15
PET chemotherapy regimen in, 21–22
potential surgical candidates in, 53–54
preoperative assessment in, 48
primary, 3
prognostic factors in, 72
radiotherapy dosing in, 32–33
radiotherapy plus PET regimen in, 22
recurrent, prognostic factors in, 72
short intensive weekly chemotherapy in, 11–12
single-agent therapy in, 72–74
surgery alone in, 48–49
surgery with adjuvant chemotherapy in, 49–50
surgical therapy of, 47–48
thoracic radiotherapy plus chemotherapy in, 26–27
tyrosine kinse inhibitor in, 81–82
V-ICE chemotherapy regimen in, 14–15
vaccination therapy in, 82–83
WHO classification of, 3–4
Small lymphocytic lymphoma, rituximab in, 439
Smoking
cessation of, approach to, 96–100
lung cancer and, 86, 94–95
nicotine addiction and, 97
nicotine replacement therapy and, 97–99
tobacco dependence and, 96
Smoldering Waldenstrom’s macroglobulinemia, 117
chlorambucil in, 236–238
clinical features of, 232
definition of, 231
natural history of, 233–234
prognostic factors for, 233
Soft-tissue sarcoma
incidence of, 413–414
recurrence patterns in, 414
surveillance following, 414–415
Somatic mutation, 138
Sonography, transrectal, and recurrent prostate cancer, 617
Spatial functioning, following chemotherapy, 750
SPECT, see Single-photon emission computed tomography
Splenectomy, in Waldenstrom’s macroglobulinemia, 124–125
Steel factor, in lung cancer, 60
Stem cell graft purging, minimal disease monitoring and, 520–522
Stem cell transplantation
allogeneic, 288, 294–295
autologous, 286–287, 291–295
chemoimmunotherapy combinations and, 527–528
stem cell collection problems for, 287
unlabeled monoclonal antibodies and, 524–527
in Waldenstrom’s macroglobulinemia, 282–284, 286–289
Step-and-shoot mode, 600
STIR technique, 629
SU5416, 60
Suberoylanilide hydroxamic acid, 309–311, 693
Surgery
breast-conserving, 802
complications of, in prostate cancer, 392–393
following chemotherapy failure, in small cell lung cancer, 52–53
following neoadjuvant chemotherapy, in small cell lung cancer, 50–51
second-look, in ovarian cancer, 406–408
in small cell lung cancer, 47–48
Surveillance, post-treatment, in curable malignancy, 337
Survival
definition of, in prostate cancer, 569
disease-specific, 569
in Waldenstrom’s macroglobulinemia, 209, 212, 213–214
TAG-72, 654–655
Tamoxifen, 767–768
bone mineral density and, 768
in early-stage breast cancer, 777–778
neurotoxicity due to, 755
second cancer following, 743
Telomerase, 654
in small cell lung cancer, 58
Teniposide, in small cell lung cancer, 72–73
TERT, 654
Thalidomide, 123
in combination therapy, 266–267
immunomodulatory derivatives of, 310–311
side effects of, 267
as single-agent therapy, 265–266
toxicity of, 272
in Waldenstrom’s macroglobulinemia, 270–273
Thiazolinediones, 311
Thiotepa
adjuvant, leukemia following, 744
cognitive effects following, 751
Thiotepa, cyclophosphamide, carboplatin regimen, cardiac effects of, 731
Three-dimensional conformal radiotherapy
biological basis of, 599–600
first-generation, computer-aided planning of, 601–603
intensity-modulated radiotherapy dose escalation study and, 605
in localized prostate cancer, 596–597
neoadjuvant androgen deprivation and, 611
in prostate cancer, 598–600
toxicity of, and intensity-modulated radiotherapy, 605–606
Thrombosis, following systemic chemotherapy, 732
Tissue biomarker, in prostate cancer, 589–590
TLC D-99, 736–737
TMPrss2, 589
Topotecan
CAV regimen v, 73, 74
in chemotherapy combination regimens, 19
oral v intravenous, 74
in small cell lung cancer, 17–18, 72–73
Topotecan, cisplatin regimen, in small cell lung cancer, 75
Tositumomab, 429
iodine 111-, 444
iodine 131-, 453, 538–541
Transcript profiling, methods of, 636
Transforming growth factor-beta, in lung cancer, 62
Transrectal sonography, and recurrent prostate cancer, 617
Transvaginal ultrasound, screening with, 344
Trastuzumab, cardiotoxicity associated with, 735–736
Treatment package, 33–34
Troglitazone, 695, 704
Troponin I, in cardiotoxicity, 734–735
Tumor, accelerated repopulation of, and chemoradiation, 28–29, 32
Tumor marker, breast cancer stage and, 341
Tumor progression, immune system failure in, 305–306
Tumor vaccination, in Waldenstrom’s macroglobulinemia, 307
Tumor vaccine
allogeneic tumor cell, 660
autologous, 660
carbohydrate, 660–661
dendritic cell, 661
DNA, 662–663
heterologous prime-boost strategy, 664
keyhole limpet hemocyanin conjugate, 660–661
protein antigen, 661
recombinant viral, 663–664
trials of, in prostate cancer, 652
using prostate cancer antigen, 655–656
Tumor-node-metastasis staging, in germ cell tumors, 383
Tumor-specific immunization, in Waldenstrom’s macroglobulinemia, 307
Two A11
in lung cancer, 62
in small cell lung cancer, 75
Tyrosine kinase inhibitor, in small cell lung cancer, 81–82
Ubiquitin ligase proteasome system, 280
Ubiquitin ligase reaction, 279
Ultrasound
of liver, colorectal cancer recurrence and, 352
transvaginal, screening and, 344
University of California Los Angeles Prostate Cancer Index, 396
Uterine cancer, screening for, as therapy complication, 344
V gene, 136
analysis of, 137–138
V-ICE chemotherapy regimen, in small cell lung cancer, 14–15
Vaccination therapy
in nicotine addiction, 100
in small cell lung cancer, 82–83
Vaccine, tumor, dendritic cell, 649, 651
Validation, 573–574
cross-, 574
definition of, 572
Vascular endothelial growth factor, 263–264
in prostate cancer, 589
Vasomotor symptoms, in breast cancer survivors, 781–785
Vegetables, potentially anticarcinogenic substances in, 88
Velaripride, 782
Venlafaxine, 782, 784
Verbal ability, following chemotherapy, 750
Verbal learning, following chemotherapy, 750
VH gene usage, 134
Vinblastine, adjuvant, leukemia following, 744
Vinblastine, estramustine regimen, in prostate cancer, 565
Vincristine
in dose-intensity trial, 13
neurotoxicity due to, 755
Vinorelbine, 73
in small cell lung cancer, 17–18
Visilizumab, 514
Visual memory, following chemotherapy, 750
Vitamin C, 793
Vitamin D, in prostate cancer, 691–692
Vitamin D receptor, 698
Vitamin D response elements, 698
Vitamin D3, 697–698
mechanisms of action of, 700–701
Volume effect, 599
Waldenstrom, Dr Jan Gosta, 107
Waldenstrom’s macroglobulinemia
age in, stem cell transplantation and, 287–288
angiogenesis in, 262–263
anti-CD22 monoclonal antibodies in, 255
asymptomatic, 117, 206–210
autologous transplantation in, 284, 294
B lymphocyte immunophenotypes in, 189–190
Bcl-2 antisense therapy in, 297–299
beta2-microglobulin levels in, 118
CD20+ B cells in, 134–135
characterization of, 116
chlorambucil in, 236–238
chromosome abnormalities in, 143
cladribine in, 237, 243–247
clarithromycin, thalidomide, dexamethasone therapy in, 270–273
classification of, 113
clinical characteristics in, 227–228
clinical features of, 188
clinicopathological definition of, 110–111
clonal B cells in, immunophenotypic profile of, 192
clonal origins in, 139–140
clonotypic IgM VDJ signature in, 134
combination chemotherapy in, 123
combination serotherapy in, 249, 251
conventional cytogenetic studies in, 142–143
cytogenetic abnormalities in, 113–114
cytomorphology in, 112
defective apoptosis in, 161–163
definition of, 107–109
diagnostic criteria for, 112, 114, 199
differential diagnosis of, 201–202
Dutcher bodies in, 183
epidemiology of, 146
factors predicting survival in, 118
familial, see Familial Waldenstrom’s macroglobulinemia
first-line therapy of, 121–122
fludarabine in, 237, 239–241
genomic stability in, 143–144
genotypic features of, 198
hematological features of, 188
hemoglobin levels in, 118
high-dose chemotherapy in, 123
high-dose chemotherapy with autologous transplantation in, 282–284, 291–295
hyaluronan in, 165–167
IgH translocations in, 142
IgM multiple myeloma v, 153–155
immunoglobulin M concentration in, 196–197
immunophenotypic definition of, 112–113
immunophenotypic features of, 197–198
immunophenotypic studies of, 185, 188–189
interphase FISH in, 143, 144
karyotype analysis in, 144
mantle cell lymphoma mimicking phenotypes of, 186
monoclonal antibody therapy in, 248–251
morphologic variants of, 184
morphological features of, 197–198
most common phenotypic profiles in, 190
multiple myeloma response criteria and, 329–331
oblimersen sodium in, 297–299, 300–303
phenotypic analysis of, 133–134
phenotypic characterization of, 132
plasma cells in, 183
plasmacytoid lymphocytes in, 183
prognostic factors in, 245–247
prognostic markers in, 118
prognostic scoring system in, 117–118
proteomic studies in, 156–159
radioimmunotherapy in, 258–260
refractory, treatment of, 239–240
relapsed, therapy of, 122–123, 239–240
rituximab therapy in, 440
serotherapy in, 248–251
short term treatment in, 118
small lymphocytes in, 183
smoldering, see Smoldering Waldenstrom’s macroglobulinemia
staging system for, 112–113
survival in, 209, 212, 213–214
thalidomide therapy in, 265–268
therapy initiation in, 119
tumor vaccination in, 307
uniform pathology in, 182
V gene analysis in, 137–138
watch-and-wait patients with, 119–120
Wayne State University preclinical model for, 313–316
Zevalin in, 259
Watchful waiting
complications of, 582
definition of, 591
in prostate cancer, 581
Women, healthy lifestyle for, 769
Women’s Healthy Eating and Living Study, 795
Women’s Intervention Nutrition Study, 794–795
World Health Organization classification
of small cell lung cancer, 3–4
of Waldenstrom’s macroglobulinemia, 107–108
XIAP, 428
YM 598, 678
Yttrium 90–epratuzumab, 459–460
Yttrium 90–ibritumomab tiuxetan, 444, 453, 534–538
expanded applicatons of, 538
ZD1839, in small cell lung cancer, 76
Zeaxanthin, chemical structure of, 87
Zevalin, 256, 258
phase I trial of, 259–260
in Waldenstrom’s macroglobulinemia, 259
Zoledronate, 770
Zoledronic acid, 692
PII: S0093-7754(03)00569-4
doi:10.1053/j.seminoncol.2003.11.007
